Skip to main content

Day: October 15, 2025

Euronet Announces Third Quarter 2025 Earnings Release Date and Conference Call Details

LEAWOOD, Kan., Oct. 15, 2025 (GLOBE NEWSWIRE) — Euronet (NASDAQ: EEFT) announced today it will release third quarter 2025 earnings results prior to the market opening on Thursday, October 23, 2025. Euronet will hold a conference call on the same day at 9 a.m. Eastern Time to discuss the results. The conference call and accompanying slide show presentation will be accessible via webcast by following the link posted on http://ir.euronetworldwide.com. Participants wanting to access the conference call by telephone must register at the Euronet Worldwide Third Quarter 2025 Earnings Call web link to receive dial-in information. While not required, it is recommended that participants join the call five minutes before the event starts. A webcast replay will be available beginning approximately one hour after the event at http://ir.euronetworldwide.com and...

Continue reading

SEALSQ Announces Pricing of $200.0 Million Registered Direct Offering & Concurrent Private Placement of Ordinary Shares and Warrants

Geneva, Switzerland, Oct. 15, 2025 (GLOBE NEWSWIRE) — Offerings to be led by Heights Capital Management, Inc. Offerings priced approximately 26.5% above market under Nasdaq rules. SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI and Post-Quantum technology hardware and software products, today announced the pricing of a $94.8 million registered offering (the “Registered Offering”) and a $105.2 million concurrent private placement (the “Private Offering” and, together with the Registered Offering, the “Offerings”). The Offerings are being led by Heights Capital Management, Inc. The Registered Offering consists of 12,640,000 ordinary shares at an offering price of $7.50. The Private Offering consists of pre-funded warrants...

Continue reading

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. Lance Alstodt, BioRestorative’s CEO, and Francisco Silva, the Company’s Vice President of Research and Development, will be participating in a panel titled “Stem Cell Therapy – A Space That is Ready to have its Day,” to be moderated by Jason McCarthy, Ph.D., Maxim Group’s Senior Managing Director, Head of Biotechnology Research. BioRestorative management will also be meeting with institutional investors in a one-on-one format during the event. Due to the format...

Continue reading

Biomerica Reports First Quarter Fiscal 2026 Financial Results

Reported Improved Gross Margin from Contribution from Higher-Margin Product MixOperating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational EfficiencyEarnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year.IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter ended August 31, 2025. Key Highlights:inFoods® IBS receives Proprietary Laboratory Analysis (“PLA”) Code The American Medical Association CPT Editorial Panel has issued a PLA code...

Continue reading

Plumas Bancorp Reports Third Quarter 2025 Earnings

RENO, Nev., Oct. 15, 2025 (GLOBE NEWSWIRE) — Plumas Bancorp (Nasdaq:PLBC), the parent company of Plumas Bank, today announced earnings during the third quarter of 2025 of $5.1 million or $0.74 per share, a decrease of $2.7 million from $7.8 million or $1.33 per share during the third quarter of 2024.   Diluted earnings per share decreased to $0.73 per share during the three months ended September 30, 2025, down from $1.31 per share during the quarter ended September 30, 2024. Net interest income increased $6.3 million in the quarter and the provision for income taxes declined by $1.1million. These items were offset by an increase of $5.8 million in the provision for credit losses and an increase of $4.3 million in non-interest expense.  The annualized return on average assets was 0.90% for the three months ended September 30, 2025,...

Continue reading

TPG & Corpay Complete Acquisition of AvidXchange

CHARLOTTE, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (“AvidXchange” or the “Company”) (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions, today announced that TPG and Corpay have completed their previously announced acquisition of the Company for $10.00 per share. The acquisition established AvidXchange as a private company valued at approximately $2.2 billion. “We are truly excited to chart the next chapter in AvidXchange’s growth trajectory with the support of TPG and Corpay. As a private company, we look forward to building upon our 25+ years of industry leadership by accelerating innovation, delivering new and enhanced solutions to our customers, and creating further opportunities for our team,” said Mike Praeger, CEO of AvidXchange. “TPG and Corpay’s...

Continue reading

Minerals Technologies Inc. Announces Increase in Quarterly Dividend; Third Consecutive Year of Dividend Increases

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) — Minerals Technologies Inc. (NYSE: MTX) (“MTI”), a leading, technology-driven specialty minerals company, today announced a 9% increase of its regular quarterly dividend on the company’s common stock to $0.12 per share. The dividend is payable on December 4, 2025, to stockholders of record at the close of business on October 30, 2025. “This is the third year in a row that MTI’s Board of Directors has authorized an increase of our quarterly dividend, reflecting our confidence in MTI’s continued ability to deliver steady cash flow, create value for shareholders, and execute on its long-term growth strategy,” said Douglas T. Dietrich, Chairman and Chief Executive Officer. MTI’s regular quarterly dividend is a key component of the company’s balanced approach to capital deployment, which includes...

Continue reading

Caldwell U.S. Dividend Advantage Fund (the “Fund”) Correction of Payment Date for the January 2026 Distribution on its ETF Series

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Oct. 15, 2025 (GLOBE NEWSWIRE) — Caldwell Investment Management Ltd., the manager of Caldwell U.S. Dividend Advantage Fund (the “Fund”), issued a news release on October 14, 2025 announcing the 2025 Q4 distributions on the Fund’s ETF Series, which consist of one payment in each of November and December 2025, and January 2026. In the news release, the payment date for the January 2026 payment was incorrectly described as January 8, 2025. The correct payment date for the January 2026 payment should be January 8, 2026. All other information in that news release remains unchanged. The table below shows the record date, payment date and payment amount of the 2025 Q4 distributions of the Fund’s ETF Series.Record Date Payment...

Continue reading

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net salesBagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) in clinical development for rare blood and kidney disorders. Under the terms of the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialise zaltenibart in all indications. Omeros is eligible...

Continue reading

Alliance Creative Group, Inc. (ACGX) Expands Digital Media Portfolio With New Acquisitions Across Hospitality, Education, and Legal Industries

Building the Future of AI-Powered Media, Marketing & Digital Assets CHICAGO, Oct. 15, 2025 (GLOBE NEWSWIRE) — via IBN – Alliance Creative Group, Inc. (OTC:ACGX) is pleased to announce the expansion of its growing digital portfolio with the acquisition of three established online websites serving the Hospitality, Education, and Legal industries. These acquisitions represent a strategic step forward in ACGX’s mission to build an AI-driven, cross-platform media ecosystem that modernizes and monetizes digital assets across multiple sectors. The transaction was completed using a combination of cash and restricted stock, and includes a consulting agreement aligning long-term interests between ACGX and the sellers. The decision by the sellers to accept restricted shares—held for over a year before being eligible for resale—demonstrates...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.